Related references
Note: Only part of the references are listed.Quantitative PCR-Based Method to Assess Cell-Free DNA Quality, Adjust Input Mass, and Improve Next-Generation Sequencing Assay Performance
Seng Lor Saelee et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US
Apar Kishor Ganti et al.
JAMA ONCOLOGY (2021)
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
Arlou Kristina Angeles et al.
NPJ PRECISION ONCOLOGY (2021)
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Ira W. Deveson et al.
NATURE BIOTECHNOLOGY (2021)
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
Paul van der Leest et al.
MOLECULAR ONCOLOGY (2021)
Imaging biomarkers for evaluating tumor response: RECIST and beyond
Ching-Chung Ko et al.
BIOMARKER RESEARCH (2021)
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
Wei Zou et al.
JCO PRECISION ONCOLOGY (2021)
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC
Michael L. Cheng et al.
JCO PRECISION ONCOLOGY (2021)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
Elisabetta Zulato et al.
BRITISH JOURNAL OF CANCER (2020)
Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
Pieter A. Boonstra et al.
CANCER AND METASTASIS REVIEWS (2020)
Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Xiaoju Max Ma et al.
CLINICAL CANCER RESEARCH (2020)
Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer
John Jiang et al.
BMC CANCER (2020)
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Barzin Y. Nabet et al.
CELL (2020)
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial
S. Hrebien et al.
ANNALS OF ONCOLOGY (2019)
Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches
Barbara Izzo et al.
FRONTIERS IN ONCOLOGY (2019)
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer
Nicolas Guibert et al.
LUNG CANCER (2019)
Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer
Jillian Phallen et al.
CANCER RESEARCH (2019)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
A method to identify somatic mutations from tumor samples in the absence of matched normal tissue
Lijing Yao et al.
CANCER RESEARCH (2018)
The ExAC browser: displaying reference data information from over 60 000 exomes
Konrad J. Karczewski et al.
NUCLEIC ACIDS RESEARCH (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Aadel A. Chaudhuri et al.
CANCER DISCOVERY (2017)
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC
Tao Jiang et al.
THERANOSTICS (2017)
Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
Martin E. Gutierrez et al.
CLINICAL LUNG CANCER (2017)
Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Fanny Garlan et al.
CLINICAL CANCER RESEARCH (2017)
Liquid Biopsy in Lung Cancer A Perspective From Members of the Pulmonary Pathology Society
Lynette M. Sholl et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Integrated digital error suppression for improved detection of circulating tumor DNA
Aaron M. Newman et al.
NATURE BIOTECHNOLOGY (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study
Nicolas Pecuchet et al.
PLOS MEDICINE (2016)
Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients
Kikuya Kato et al.
SCIENTIFIC REPORTS (2016)
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
J. Tie et al.
ANNALS OF ONCOLOGY (2015)
A global reference for human genetic variation
David M. Altshuler et al.
NATURE (2015)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Levels of cell- free DNA and plasma KRAS during treatment of advanced NSCLC
Anneli Dowler Nygaard et al.
ONCOLOGY REPORTS (2014)
Early Response to Chemotherapy in Patients With Non-Small-Cell Lung Cancer Assessed by [18F]-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography
Silvia Novello et al.
CLINICAL LUNG CANCER (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer
Andrea Ardizzoni et al.
CANCER (2006)
Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy
John F. Bruzzi et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
dbSNP: a database of single nucleotide polymorphisms
EM Smigielski et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
